Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Opicinumab add-on therapy in relapsing multiple sclerosis
NL-OMON48632Phase 2Active, not recruiting
- Sponsor
- Biogen
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of opicinumab in multiple sclerosis (MS), secondary-progressive multiple sclerosis (SPMS), sponsored by Biogen. Started Apr 2018; status: active, not recruiting.
02
Drugs
opicinumab
03
Conditions
multiple sclerosis (MS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NL-OMON48632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48632.